b'Reveal hidden proteomic insightsIdentify unique biomarkers with early predictive insightsUnderstanding phenotypic and functional biological variation can generate actionable insights into molecular mechanisms and disease pathogenesis that refine targeted therapies and advance precision medicine approaches. For this reason, clinical researchers are including CyTOF in their clinical trials to better understand disease activity, drug response or outcome prediction. CASE STUDYIn a Phase 1 clinical trial 1 , CyTOF technology reveals predictive biomarkers of response and survival for checkpoint therapy in advanced non-small-cell lung carcinoma.1.00Survival probability (OS)0.750.500.25 P 0.00010.000 50 100 150 200 250 300 350Time in daysStrata BIPS = 0 BIPS = 1 BIPS = 2 BIPS = 3Figure 1. CyTOF technology demonstrates that blood baseline frequencies of classical monocytes, natural killer cells and ICOS+ CD4+ T cells are significantly associated with improved objective response rates, progression-free survival and overall survival.Rochigneux, P. et al. Clinical Cancer Research (2022)'